Literature DB >> 3081367

Plasminogen activators catalyse conversion of inhibitor from fibrosarcoma cells to an inactive form with a lower apparent molecular mass.

L S Nielsen, P A Andreasen, J Grøndahl-Hansen, L Skriver, K Danø.   

Abstract

Purified approximately 54 kDa plasminogen activator inhibitor from human fibrosarcoma cells was converted to an inactive form with slightly higher electrophoretic mobility by incubation with catalytic amounts of urokinase-type or tissue-type plasminogen activator. Serine proteinase inhibitors and a monoclonal antibody against urokinase-type plasminogen activator inhibited the conversion, indicating that it was caused by plasminogen activator-catalyzed proteolysis. These findings represent the first demonstration of a well-defined protein apart from plasminogen, constituting a substrate for plasminogen activators.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3081367     DOI: 10.1016/0014-5793(86)80261-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  11 in total

1.  Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma.

Authors:  P Kristensen; C Pyke; L R Lund; P A Andreasen; K Danø
Journal:  Histochemistry       Date:  1990

2.  Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells.

Authors:  B S Knudsen; P C Harpel; R L Nachman
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

3.  Urokinase-dependent adhesion loss and shape change after cyclic adenosine monophosphate elevation in cultured rat mesangial cells.

Authors:  W F Glass; R A Radnik; J A Garoni; J I Kreisberg
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

4.  MUC1 protein induces urokinase-type plasminogen activator (uPA) by forming a complex with NF-κB p65 transcription factor and binding to the uPA promoter, leading to enhanced invasiveness of cancer cells.

Authors:  Yugo Mori; Kaoru Akita; Shuhei Tanida; Akiko Ishida; Munetoyo Toda; Mizue Inoue; Masakazu Yashiro; Tetsuji Sawada; Kosei Hirakawa; Hiroshi Nakada
Journal:  J Biol Chem       Date:  2014-11-04       Impact factor: 5.157

5.  Plasminogen activator inhibitor type I stabilizes vitronectin-dependent adhesions in HT-1080 cells.

Authors:  G J Ciambrone; P J McKeown-Longo
Journal:  J Cell Biol       Date:  1990-11       Impact factor: 10.539

6.  The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells.

Authors:  O Saksela; D Moscatelli; D B Rifkin
Journal:  J Cell Biol       Date:  1987-08       Impact factor: 10.539

7.  Regulation of the synthesis and activity of urokinase plasminogen activator in A549 human lung carcinoma cells by transforming growth factor-beta.

Authors:  J Keski-Oja; F Blasi; E B Leof; H L Moses
Journal:  J Cell Biol       Date:  1988-02       Impact factor: 10.539

8.  Plasminogen activator-specific inhibitors produced by human monocytes/macrophages.

Authors:  A Wohlwend; D Belin; J D Vassalli
Journal:  J Exp Med       Date:  1987-02-01       Impact factor: 14.307

9.  Association of a plasminogen activator inhibitor (PAI-1) with the growth substratum and membrane of human endothelial cells.

Authors:  E G Levin; L Santell
Journal:  J Cell Biol       Date:  1987-12       Impact factor: 10.539

10.  Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis.

Authors:  H Yoshino; Y Endo; Y Watanabe; T Sasaki
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.